Skip to Content

Canopy Growth Corp CGC

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Low Probability and Materiality of ESG Risks Leaves Canopy’s FVE and Uncertainty Rating Intact

Analyst Note

| Kristoffer Inton |

After updating Canopy for our latest methodologies, we find minimal valuation impact from environmental, social, and governance risk and assign a Standard capital allocation rating. We maintain our $30 and CAD 38 per share fair value estimates and no-moat rating. Shares look undervalued in 4-star territory even after considering Canopy’s very high uncertainty rating.

Read Full Analysis

Company Profile

Business Description

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.

Contact
1 Hershey Drive
Smiths Falls, ON, K7A 0A8, Canada
T +1 855 558-9333
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2021
Fiscal Year End Mar 31, 2022
Stock Type
Employees 3,259

Related